Philadelphia College of Pharmacy has Two Research Projects Funded by Merck
Published on June 4, 2020
USciences’ Assistant Professor of Clinical Pharmacy Islam Ghazi PharmD, BCPS, BCACP, and students from the Philadelphia College of Pharmacy (PCP) have had two research projects funded by Merck & Co., whose mission is to discover, develop, and provide innovative products and services that save and improve lives around the world.
The first project, titled Y-site Administration of Imipenem/Cilastatin/Relebactam With Common Intravenous Medications has been completed and published by the reputable pharmacy journal, Clinical Therapeutics. In this study, Dr. Ghazi and PCP pharmacy students looked at the use of Imipenem/Cilastatin/Relebactam for the treatment of hospital-acquired and ventilator-associated pneumonia, specifically looking to see if Imipenem/Cilastatin/Relebactam would have any adverse reactions to other intravenous medications given to the patient. In addition to their publication, the findings of this study will be included in Trissel’s IV compatibility database to guide administration protocols for the medications listed.
The second project, entitled Is Bezlotoxumab effective, safe and cost saving in preventing recurrent Clostridium difficile infections in patients with malignancies. An exploratory study. has been selected by Merck to receive a $60,000 grant.